Maribavir single box price range

Maribavir (Maribavir) is an innovative antiviral drug developed by Takeda Pharmaceuticals. It is mainly used to treat cytomegalovirus (CMV) infections that occur after adult hematopoietic stem cell transplantation or solid organ transplantation, especially in patients who are resistant or intolerant to other antiviral drugs (such as ganciclovir, foscarnet, or cidofovir). Its unique UL97 kinase inhibition mechanism enables it to show a higher balance of safety and efficacy in clinical practice, and is considered a major advancement in the management of post-transplant infection.

Currently, maribasvir tablets have been officially launched in China and have been included in the medical insurance catalog. The drug specification is200mg*56 tablets of the original US version. According to public market information, the domestic price of drugs of this specification is approximately RMB 29,000, making it one of the higher-priced imported antiviral drugs. In comparison, the European version of original maribavivir is more expensive in overseas markets. The retail price of drugs of the same specification in the European market is equivalent to about hundreds of thousands of yuan, which will be adjusted due to regional policies, exchange rate fluctuations and channel differences. There are currently no generic versions on the market.

The clinical application of maribavivir is mainly concentrated in patients with suppressed immune systems, especially individuals with recurrence of CMV infection after transplantation. Its administration method is oral, usually twice a day. Compared with traditional drugs, it does not require intravenous injection, which significantly improves patients' compliance and quality of life. Studies have shown that maribavivir has good and sustained efficacy in clearing CMV DNA from the blood and improving viral symptoms. At the same time, it is not likely to cause neutropenia or nephrotoxicity, which is particularly important in patients under immunosuppression.

With the support of medical insurance policies, the actual cost of maribavivir has dropped significantly compared with its early importation, providing more patients with an accessible treatment option. Although the price of a single box is still high, its short treatment cycle and significant efficacy make the overall economic burden relatively controllable.

Reference materials:https://www.livtencity.com/